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Edited by Gianni CesareniAbstract Searching for CCN family protein 2/connective tissue
growth factor (CCN2/CTGF) interactive proteins by yeast-two-
hybrid screening, we identiﬁed ﬁbronectin 1 gene product as a
major binding partner of CCN2/CTGF in the chondrosarcoma-
derived chondrocytic cell line HCS-2/8. Only the CT domain
of CCN2/CTGF bound directly to ﬁbronectin (FN). CCN2/
CTGF and its CT domain enhanced the adhesion of HCS-2/8
cells to FN in a dose-dependent manner. The CCN2/CTGF-
enhancing eﬀect on cell adhesion to FN was abolished by a block-
ing antibody against a5b1 integrin (a5b1), but not by one against
anti-avb3 integrin. These ﬁndings suggest for the ﬁrst time that
CCN2/CTGF enhances chondrocyte adhesion to FN through di-
rect interaction of its C-terminal CT domain with FN, and that
a5b1 is involved in this adhesion.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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CCN family protein 2/connective tissue growth factor
(CCN2/CTGF) regulates cell adhesion, migration, prolifera-
tion, survival, diﬀerentiation, and gene expression in a number
of cell types isolated from tissues, including chondrocytes
[1]. CCN2/CTGF is a member of the CCN family (Cyr61,
CTGF, Nov); it is strongly expressed in growth plate cartilage,
especially in hypertrophic chondrocytes [1,2]. Multiple func-
tions of CCN2/CTGF have been reported such as stimulation
of cartilage-speciﬁc extracellular matrix synthesis, chondrocyteAbbreviations: CCN2/CTGF, CCN family protein 2/connective tissue
growth factor; avb3, integrin avb3; a5b1, integrin a5b1; FN, ﬁbro-
nectin; BSA, bovine serum albumin
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doi:10.1016/j.febslet.2006.01.061proliferation, and angiogenesis [2,3]. In CCN2/CTGF null mu-
tant mice, osteogenesis is inhibited due to impaired chondro-
genesis and growth plate angiogenesis [1]. The axial skeletal
defects lead to neonatal respiratory failure and death within
minutes of birth. Little is known, however, about the CCN2/
CTGF interactions with chondrocytes or about the transmem-
brane receptors or signalling pathways that are able to trans-
duce CCN2/CTGF-derived signals and mediate their
activities in chondrocytes. Recently, it was shown that CCN2/
CTGF promotes ﬁbroblast adhesion to ﬁbronectin (FN) and
binds to FN as well as to its receptors a4b1 and a5b1 integrins
and to syndecan [4]. Furthermore, it induces adhesion of hepa-
tic cells by direct binding to the integrin receptor avb3 and to
heparansulfate proteoglycan through its C-terminal, heparin-
binding domain [5]. There also is a report that CCN2/CTGF
signalling occurs through LRP1, an endocytotic receptor [1].
In order to identify additional extracellular or cell-surface
targets for CCN2 that may be involved in the regulatory func-
tions of CCN2/CTGF in chondrocytes, we searched for
CCN2/CTGF-binding proteins by using the yeast two-hybrid
screening assay. A cDNA library derived from human chon-
drosarcoma-derived chondrocytic cell line HCS-2/8 was
screened for CCN2/CTGF binding since this cell line has a dif-
ferentiated phenotype similar to that of normal chondrocytes
in terms of aggrecan- and cartilage collagen secretion and inte-
grin expression proﬁles, e.g., a2b1 and a5b1 [6]. Among several
extracellular matrix proteins we identiﬁed ﬁbronectin 1 gene
during the screening, a major cell-surface protein found also
on chondrocytes [7].
In this paper, we show for the ﬁrst time that (1) direct
CCN2/CTGF binding to FN occurred through the C-terminal
heparin-binding CT domain, the same domain that also binds
to integrins avb3 and a5b1 (avb3 and a5b1) in ﬁbroblasts [5];
(2) CCN2/CTGF as well its C-terminal heparin-binding do-
main enhanced HCS-2/8 chondrocytic cell adhesion to FN in
a dose-dependent manner; and (3) the enhancing activity could
be impaired by a monoclonal antibody against the CT domain
and by an antibody against a5b1, but not by anti-avb3.2. Materials and methods
2.1. Yeast two-hybrid cDNA library screening
Full-length and truncated cDNAs of ccn2/ctgf were prepared as baits
by PCR ampliﬁcation and cloned into the pGBKT7 vector containing
the DNA-binding domain of GAL4. For screening, a cDNA libraryblished by Elsevier B.V. All rights reserved.
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EcoRI site of the pGADT7 vector. A total of 1 · 106 independent cDNA
clones with an average insert size of 2.4 kbp (range: 2.0–4.0 kbp) was
obtained.Aliquots of 50 lg of the resulting cDNA librarywere thenused
individually to transform AH109 yeast cells that had been transformed
with a CCN2/CTGF-bait containing amino acid residues 27–349 and
screened on selection plates lacking leucine, tryptophan, histidine, and
adenine but containing 3-AT and X-gal. After 3–5 days incubation,
positive clones were picked, and plasmidDNAwas used to re-transform
Escherichia coli DH5a strain for further cloning and sequencing. The
primers used for ampliﬁcation of full-length and truncated forms of
ccn2/ctgf were the following. CCN2full (27–349): 5
0-atccgaattccagaactg-
cagcgggccgtgccggtgcccg-3 0 and 5 0-atacggatccctcatgccatgtctccgtacatctt-
cctgt-30; CCN2IGFBP (27–101): 5 0-atccgaattccagaactgcagcgggccgtg-
ccggtgcccg-3 0 and 5 0-atacggatccgagcaccatctttggcggtgcacacgccga-3 0;
CCN2VWC (94–198): 5
0-atccgaattcgtgtgcaccgccaaagatggtgctccctgc-3 0
and 50-atacggatccagttggctctaatcatagttgggtctgggc-30; CCN2TSP (193–258):
50-atccgaattcactatgattagagccaactgcctggtccaga-30 and 50-atacggatccggat-
gcactttttgcccttcttaatgttct-3 0; CCN2CT (249–349): 5 0-atccgaattcaacattaa-
gaagggcaaaaagtgcatccgt-30 and 5 0-atacggatccctcatgccatgtctccgtacatcttc-
ctgt-3 0.
All CCN2/CTGF peptides were expressed as a c-Myc epitope-fused
form, and the expression of each protein in yeast was conﬁrmed by
Western blotting using anti-Myc antibody and cell lysates from yeast
transformants (data not shown).
2.2. Cell culture and DNA transfection
HCS-2/8 human chondrocytic cells were maintained as described
before [8,9]. Transient transfection experiments were performed by
using Fugene 6 (Roche, Indianapolis, IN). pFlag/mCCN2-3HA,
which expressed mouse CCN2/CTGF containing multimerized HA-
epitope tag on its C-terminus, was prepared by PCR using primers
5 0-ccgcgaattcaatgctcgcctccgtcgcaggtcccatc-3 0 and 5 0-cccgggatcctctagat-
taagatctcgccatgtctccgtacatcttcct-3 0, and linkage of BamHI-tacccatac-
gatgttccagattacgctagatcc tacccatacgatgttccagattacgctagatcc tacccatac-
gatgttccagattacgct-BglII, and insertion into the pFlag-CMV2 vector.
2.3. Cell attachment and antibody blocking assays
HCS-2/8 cells were trypsinized, washed, and suspended at a cell
density of 2 · 105/ml in DMEM containing various concentrations
of recombinant CCN2/CTGF [3], or CT [10], or bovine serum albu-
min (BSA) and/or antibodies. Twelve-well plates were coated with
human recombinant FN (Becton Dickinson, NJ) for 16 h and
blocked with 1% BSA in PBS, pH 7.3, for 1 h. One milliliter of the
cell suspension was introduced into the wells, and the cells were then
allowed to attach for 30 min at 37 C. Unbound cells were removed
by washing with PBS 3 times; and the attached cells were then col-
lected, centrifuged, resuspended, and counted. For antibody blocking
assays, the following antibodies were used: JMab {a monoclonal anti-
body against the CT domain which was kindly provided by JT Cen-
tral Pharmaceutical Research Institute (Takatsuki, Japan), also see
[10]}, control antibody (anti-Flag epitope monoclonal antibody, Sig-
ma), anti-avb3 (LM609, Chemicon, CA), and anti-a5b1 (JBS5,
Chemicon).
2.4. Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were done as described
previously [8,9]. For in vitro binding, 0.3 lg of recombinant CCN2/
CTGF and/or 2 lg of recombinant FN were incubated in binding buf-
fer (10 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.1% NP-40, 0.5% BSA)
containing 3 lg of anti-FN antibody (BD Biosciences, CA) at 4 C for
30 min. For in vivo binding, HCS-2/8 cells transfected with Flag and
HA-tagged CCN2/CTGF were harvested in lysis buﬀer (50 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1%
Triton-X100) and incubated with 2 lg of anti-HA antibody (Covance,
CA). Immuno-complexes were precipitated by protein G agarose
(Amersham Biosciences, NJ).2.5. Solid-phase binding assay
Maxisorp ELISA plate wells were coated with 100 ll of 1 lg/ml re-
combinant CCN2/CTGF and CT peptide in 50 mM NaHCO3 buﬀer
(pH 9.6) at 4 C overnight, and blocked with 200 ll of binding buﬀer
(50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 2% BSA, 0.05% Tween20)for 3 h at 37 C. Biotinylated and/or unlabeled FN were added to
the wells in a total volume of 100 ll of binding buﬀer and incubated
for 6 h at 37 C. The wells were washed with binding buﬀer and then
incubated with 100 ll of streptavidin-HRP (R&D Systems, MN).
Bound HRP was monitored using TMD peroxidase substrate kit
(Bio-Rad, CA).2.6. Immunoﬂuorescence of cell-surface proteins
HCS-2/8 cells transfected with Flag and HA-tagged CCN2/CTGF
were grown on glass slides, and cell-surface immunoﬂuorescence
staining was done as previously [8,9]. After mounting, the protein
localization was observed by using a confocal Laser scanning micro-
scope (Bio-Rad).3. Results
3.1. FN interacts with CCN2/CTGF through the CT domain
To identify CCN2/CTGF-binding proteins, we carried out
GAL4-based yeast two-hybrid screening using human
chondrocytic cell line, HCS-2/8 and ccn2/ctgf cDNA frag-
ment (a.a.res. 27–349) as a bait. As a result, ﬁbronectin 1 gene
product was identiﬁed as one of the CCN2/CTGF-binding
proteins among 50000 individual clones. The C-terminal half
of FN was suﬃcient for binding to CCN2/CTGF (Fig. 1A).
To conﬁrm the speciﬁcity of this interaction, we sought to
identify the FN-interacting sites in the CCN2/CTGF mole-
cule which consists of 4 domains. For this purpose, full-
length CCN2/CTGF (‘‘full’’, Fig. 1A) and its subdomains
were expressed in AH109 yeast cells as GAL4-DNA-binding
domain (GAL4 BD)-fusion proteins (Fig. 1A). The strongest
binding to FN1 was achieved with the full-length CCN2/
CTGF (CCN2full) and a fragment containing the CT domain
(CCN2CT). Relatively weaker binding was obtained with the
VWC domain (CCN2VWC), whereas the IGFBP
(CCN2IGFBP) and TSP1 (CCN2TSP1) domains did not show
any interaction (Fig. 1B). Direct binding between recombi-
nant CCN2/CTGF and FN in vitro was conﬁrmed in a
pull-down assay using anti-FN and anti-CCN2/CTGF
(Fig. 1C). Additionally, FN binding to CCN2/CTGF was
shown in vivo in a pull-down assay with HA-tagged CCN2/
CTGF expressed in HCS-2/8 cells (Fig. 1D). We also investi-
gated the ability of full length or CT domain of CCN2/
CTGF to bind FN in a solid phase (Fig. 1E). Biotinylated re-
combinant FN was bound eﬀectively to full length CCN2/
CTGF or CT domain coated on microplate wells. In the pres-
ence of unlabeled competitor, FN binding decreased in a
dose-dependent manner (Fig. 1E). Taken together, these re-
sults conﬁrm a direct interaction between FN and CCN2/
CTGF, especially with the CT domain.3.2. CCN2/CTGF enhances cell adhesion to FN
In order to test the possibility that the aﬃnity of CCN2/
CTGF for FN aﬀected the cell adhesion of chondrocytes to
FN, we plated HCS-2/8 cells on microtiter dishes coated
with increasing amounts of FN in the presence or absence
(‘‘control’’) of CCN2/CTGF and allowed them to adhere
for 30 min. Fig. 2A shows that HCS-2/8 cells attached to
FN in a dose-dependent manner and that this adhesion
was enhanced in the presence of CCN2/CTGF. Similarly,
adhesion of HCS-2/8 cells to a constant amount of FN
was enhanced by increasing amounts of CCN2/CTGF
(Fig. 2B).
Fig. 1. Interaction between CCN2/CTGF and ﬁbronectin 1 (FN1) gene product. (A) Vector constructs of CCN2/CTGF and its fragments which were
expressed as GAL4-DNA binding domain (BD)-fusion proteins, and of FN1 fragment which was expressed as GAL4-transactivation domain (AD)-
fusion protein for two-hybrid assay in yeast AH109. Numbers are positions of amino acid from the start codon. (B) Growth test of yeast
transformants for interaction between CCN2/CTGF fragments and FN1 in selection media (SD/-Ade, -His, -Leu, -Trp). Right: The combinations of
GAL4-BD-fusion proteins and GAL4-AD proteins. Left: Left column in each block of CCN2/CTGF fragment contains GAL4-DNA AD (mock)
and right column contains GAL4-AD/FN1 transformant. Cell growth was observed to be strong in transformants containing FN1 with CCN2full or
CCN2CT. Relatively weak growth was observed for CCN2VWC and FN1 transformants. (C) In vitro binding of CCN2/CTGF to FN. Complexes of
CCN2/CTGF and FN were pulled down by anti-FN antibody, and CCN2/CTGF was detected by using anti-CCN2/CTGF antibody. Five percent of
total input proteins and proteins immunoprecipitated with anti-FN antibody (BD Biosciences) were loaded on SDS–PAGE gels and electrophoresed;
and CCN2/CTGF was detected by its speciﬁc antibody. In the presence of FN, CCN2/CTGF was pulled down eﬀectively by anti-FN antibody as
compared with control. (D) In vivo binding of CCN2/CTGF to FN. Overexpressed, HA-tagged CCN2/CTGF and binding proteins were precipitated
from HCS-2/8 cell lysates by using HA antibody (Covance, PV). Among the precipitated CCN2/CTGF binding proteins, FN was detected. (E) Solid-
phase binding of FN to CCN2/CTGF or its CT domain immobilized on microplates. Microplate wells coated or non-coated with 1 lg/ml of
recombinant human CCN2/CTGF or CT domain were incubated with biotinylated (left) or together with biotinylated and unlabeled (right)
recombinant human FN at concentrations indicated. Binding of biotinylated FN was quantiﬁed by colorimetric assay at A405 using streptavidin-
HRP.
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Fig. 2. CTGF/CCN2 enhances cell adhesion to FN. (A) Dishes were coated with 1 lg/ml or 2 lg/ml of FN and incubated with 2 · 105 HCS-2/8 cells
in the presence of 200 lg/ml recombinant CCN2/CTGF (CCN2) or without CCN2 (control, BSA 200 lg/ml). After a 30-min incubation, adhesive
cells were counted. *P < 0.01, **P < 0.03 (student’s t test). (B) Dishes were coated with 2 lg/ml of FN and incubated with 2 · 105 HCS-2/8 cells in the
presence of 40 lg/ml or 200 lg/ml recombinant CCN2/CTGF (CCN2) or without CCN2 (control, BSA 40 lg/ml or 200 lg/ml). Control value was
subtracted from each concentration of CCN2/CTGF. §P < 0.006, §§P < 0.002 (student’s t test). (A, B) Data in the ﬁgures are representative of 3
experiments yielding similar results.
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domain
In Fig. 3A we show that the recombinant CT domain
(200 lg/ml) enhanced cell adhesion to FN, indicating that
the CT domain did not block the integrin-binding site in the
FN molecule, but may have served as a bridging molecule be-
tween FN and integrins. The speciﬁcity of the CT domain in
supporting cell adhesion to FN was conﬁrmed by using a
monoclonal antibody against the CT domain (JMab). When
the antibody was added to the HCS-2/8 cell suspension along
with CCN2/CTGF, it abolished the adhesion-enhancing eﬀect
of CCN2/CTGF on cell adhesion to FN (Fig. 3B).
3.4. CCN2/CTGF is colocalized with FN
In order to support our notion that CCN2/CTGF enhances
chondrocyte binding to both FN and its receptors, we analyzed
the subcellular localization of these factors in chondrocytes by
cell-surface immunoﬂuorescence. For this experiment, HCS-2/8
cells were transiently transfected with an HA-tagged CCN2/Fig. 3. Enhancement of cell adhesion to FN by CT domain and inhibitio
antibody against the CT domain of CCN2/CTGF (JMab). (A) The cell adh
adding 200 lg/ml of BSA (control) or 200 lg/ml of CCN2/CTGF (CCN2) or
**P < 0.005 (student’s t test). (B) The cell adhesion to FN-coated plates (2
(JMab, 22.5 lg/ml) or a control monoclonal-antibody (anti-Flag epitope antib
(control, 200 lg/ml) to cell suspensions (2 · 105 cells). By the addition of JM
§P < 0.05, §§P < 0.00005 (student’s t test).CTGF expression vector. HCS-2/8 cells were shown previously
to express a5b1 integrin on their surface [6], and here we dem-
onstrate by Western blotting of HCS-2/8 cell lysates that they
also expressed avb3 (Fig. 4A).
The cell surface immunoﬂuorescence analysis revealed co-
distribution of CCN2/CTGF and FN on the HCS-2/8 cell sur-
face, while avb3 was not co-localized completely with CCN2/
CTGF and FN (Fig. 4B). There was, however, complete co-
localization of a5b1 with these molecules (Fig. 4B).
3.5. CCN2/CTGF enhances cell adhesion of HCS-2/8 cells to FN
mainly through a5b1, not through avb3
To clarify whether the enhancement of cell adhesion to FN
by CCN2/CTGF involved avb3 or a5b1 receptors or both,
we carried out cell adhesion experiments using blocking anti-
bodies for avb3 [11] and a5b1 subunits. The anti-avb3 had
no eﬀect on the CCN2/CTGF-enhancement of cell adhesion
of HCS-2/8 cells to FN (Fig. 5A), whereas the anti-a5b1 anti-
body abolished this enhancing eﬀect (Fig. 5B). As expected,n of CCN2/CTGF-mediated cell adhesion to FN with a monoclonal
esion to ﬁbronection-coated plates (2.0 lg/ml) was compared after the
200 lg/ml of CT peptide to cell suspensions (2 · 105 cells). *P < 0.015,
.0 lg/ml) was compared after adding a CT-domain-speciﬁc antibody
ody, cont.ab, 22.5 lg/ml) along with CCN2/CTGF (200 lg/ml) or BSA
ab, the cell adhesion to FN enhanced by CCN2/CTGF was reduced.
Fig. 4. Expression and subcellular localization of avb3, a5b1, and FN proteins in HCS-2/8 cells. (A) HCS-2/8 cell lysates (20 lg protein) were mixed
with SDS-buﬀer under reducing and non-reducing conditions, and avb3 was detected by using avb3 antibody LM609. avb3 antibody shows bands of
94 kDa (non-reduced) and 105 kDa (reduced) corresponding to b3. (B) Cell-surface localization of CCN2/CTGF (anti-HA antibody), FN, avb3, and
a5b1 (JBS5). FN, CCN2/CTGF, and integrins were detected by each speciﬁc antibody on alive HCS-2/8 cells. FN and CCN2/CTGF, but not avb3
and CCN2/CTGF, show good co-localization on the cell surface, whereas a5b1 shows good co-localization with CCN2/CTGF.
Fig. 5. Eﬀect of anti-avb3 and anti-a5b1 on cell adhesion to FN enhanced by CCN2/CTGF. The cell adhesion to FN (2 lg/ml)-coated plates was
compared after adding avb3 antibody (4.2 lg/ml, A), a5b1 antibody (4.2 lg/ml, B) or a control monoclonal-antibody (anti-Flag epitope antibody,
4.2 lg/ml) along with CCN2/CTGF (200 lg/ml) or BSA (control, 200 lg/ml) to cell suspensions (2 · 105 cells). Enhancement of cell adhesion to FN
by CCN2/CTGF was not inhibited by the addition of avb3 antibody, but was partially inhibited by a5b1 antibody. *P < 5 · 105 (student’s t test).
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BSA was added instead of CCN2/CTGF (Fig. 5B).4. Discussion
With the goal to identify functional modiﬁers of CCN2/
CTGF, we found ﬁbronectin 1 gene product as a CCN2/CTGF
interactive protein. Although there have been some reportsshowing enhancement of cell adhesion to FN by CCN2/CTGF
in ﬁbroblast [4], there has been no report showing direct molec-
ular interaction between CCN2/CTGF and FN. We also
showed for the ﬁrst time that the main FN binding domain
of CCN2/CTGF is its C-terminal CT domain. CCN2/CTGF
and its CT domain enhanced adhesion of the human chondro-
cytic cells to FN in a dose-dependent manner. This eﬀect was
abolished with a monoclonal antibody speciﬁc for the CT
domain and by anti-a5b1, suggesting that CCN2/CTGF
M. Hoshijima et al. / FEBS Letters 580 (2006) 1376–1382 1381enhances chondrocyte adhesion to FN through direct interac-
tion of its CT domain with FN. These results also suggest that
a5b1 is involved in the adhesion.
FN is one of the most widespread adhesive extracellular
glycoproteins that bind to cell surfaces and various extracel-
lular compounds including collagen, ﬁbrin, heparin (for a re-
view, see Ref. [12]). FNs control a number of cellular events,
such as cell adhesion, cell motility, maintenance of cell shape,
proliferation, and diﬀerentiation, and also involved in numer-
ous physiological and pathological processes, for example, in
growth and development, wound healing, tumorigenesis,
inﬂammation, and tissue repair. Cell interactions with FN
are mediated mostly by b1 integrins (a4b1, a5b1), av inte-
grins (avb3, avb5, avb8) [13], and other extracellular matrix
components. a5b1 is found on most epithelial and mesenchy-
mal cells including chondrocytes [14]. Like a5b1, the avb3
recognizes the RDG motif present in multiple extracellular
proteins including FN; but while a5b1 is a receptor speciﬁc
for FN, avb3 recognizes additional RGD-containing proteins
such as vitronectin, osteopontin, ﬁbrinogen, and others [14].
Both avb3 and a5b1 have been identiﬁed in chondrocytes
[14,15].
The adhesion-enhancing eﬀect of CCN2/CTGF was caused
by the aﬃnity of CCN2/CTGF for FN-binding integrins
(Fig. 5). Recently CCN2/CTGF was shown to bind to a4b1
and a5b1, the major FN receptors [4]. Gao and Brigstock [5]
demonstrated that the C-terminal heparin-binding domain of
CCN2/CTGF binds to avb3. Our results indicate, however,
that only a5b1 but not avb3 is involved in CCN2/CTGF-en-
hanced chondrocyte adhesion to FN, although HCS-2/8 cells
expressed both avb3 and a5b1 (Figs. 4 and 5). Overexpressed
CCN2/CTGF showed complete co-localization with FN as
well as with a5b1 on the surface of HCS-2/8 cells, whereas
CCN2/CTGF was only partially co-localized with avb3
(Fig. 4B), also supporting our ﬁnding that only a5b1 is in-
volved in CCN2/CTGF-enhanced chondrocyte adhesion to
FN. Interestingly, Danen et al. [16] reported that a region of
FN which is not the cell binding domain is required for
a5b1-mediated, but not avb3-mediated focal contact forma-
tion. Furthermore, they showed that the extracellular domain
of b1 but not of b3 controls Rho activity which is involved in
focal adhesion [16]. In the present study we also showed a5b1
but not avb3 on focal contacts. These ﬁndings suggest that the
CT domain of CCN2/CTGF may serve as a bridging protein
between FN and the extracellular domain of a5b1, thus
enhancing cell adhesion to FN and triggering Rho activity.
The CCN2/CTGF-binding site(s) in FN need to be investi-
gated.
The monoclonal antibody JMab did not impair cell adhesion
to FN in the absence of CCN2/CTGF (data not shown), and
the CT peptide did not block, but rather enhance cell adhesion,
indicating that the FN binding domains in avb3 [17] or in a5b1
[18] are not competed by the CT domain of CCN2/CTGF.
These ﬁndings indicate that CCN2/CTGF supports integrin-
FN binding by forming a ternary complex. In light of the re-
sults by Danen et al. [16], one can hypothesize that additional
allosteric change in the conformation of a5b1 is caused by di-
rect binding of the CT domain, resulting in partial integrin
activation [19]. It is also possible, however, that CCN2/CTGF
induces conformational changes in the FN molecule, resulting
in enhanced FN-integrin binding.There is ample evidence that CCN2/CTGF regulates further
cell functions including proliferation, matrix synthesis, and
angiogenesis, as well as chondrogenic and osteogenic diﬀeren-
tiation [1–3]. Since the monoclonal antibody JMab against the
CT domain, which inhibited the cell adhesion-promoting activ-
ity of CCN2/CTGF, also inhibits proteoglycan synthesis and
cell proliferation of chondrocytes [10], the CT domain itself
may have a responsibility for some of those biological pro-
cesses. Whether all these eﬀects are mediated via integrin sig-
naling is going to be investigated.
CCN2/CTGF has been shown to be involved in several steps
of cartilage development including mesenchymal condensa-
tion, chondrogenesis, and endochondral ossiﬁcation. Also, as
FN is expressed in prechondrogenic limb mesenchyme [7]
and in fetal and adult cartilage [20], where it may have a role
in chondrogenic diﬀerentiation [20], it is likely that CCN2/
CTGF binding to FN may be an additional control factor in
chondrocyte diﬀerentiation.
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